Quince Therapeutics, Inc.QNCXNASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
23.35%
↑ 129% above average
Average (30q)
10.18%
Historical baseline
Range
High:139.97%
Low:-65.95%
Volatility
2022.8%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 23.35% |
| Q2 2025 | -19.55% |
| Q1 2025 | 39.83% |
| Q4 2024 | 18.49% |
| Q3 2024 | 18.54% |
| Q2 2024 | 12.02% |
| Q1 2024 | 7.80% |
| Q4 2023 | 139.97% |
| Q3 2023 | 5.76% |
| Q2 2023 | -58.11% |
| Q1 2023 | 16.69% |
| Q4 2022 | 12.93% |
| Q3 2022 | -65.95% |
| Q2 2022 | -43.57% |
| Q1 2022 | -16.14% |
| Q4 2021 | 8.37% |
| Q3 2021 | -4.63% |
| Q2 2021 | -12.51% |
| Q1 2021 | 6.10% |
| Q4 2020 | -6.63% |
| Q3 2020 | 20.57% |
| Q2 2020 | -2.04% |
| Q1 2020 | 43.41% |
| Q4 2019 | 21.50% |
| Q3 2019 | 16.09% |
| Q2 2019 | 47.34% |
| Q1 2019 | 55.85% |
| Q4 2018 | 35.20% |
| Q3 2018 | 0.17% |
| Q2 2018 | -5.26% |
| Q1 2018 | 0.00% |